US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018
暂无分享,去创建一个
[1] K. Lieb,et al. Impact of physicians’ participation in non-interventional post-marketing studies on their prescription habits: A retrospective 2-armed cohort study in Germany , 2020, PLoS medicine.
[2] H. Krumholz,et al. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017 , 2020, JAMA network open.
[3] M. Herder. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency , 2019, The Milbank quarterly.
[4] J. Wallach,et al. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis , 2019, BMC medicine.
[5] R. Pazdur,et al. Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA). , 2019, Journal of Clinical Oncology.
[6] J. Wallach,et al. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments , 2019, JAMA network open.
[7] J. Mogil,et al. Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review , 2019, JAMA internal medicine.
[8] Lisa M. Schwartz,et al. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis , 2018, Journal of General Internal Medicine.
[9] G. Baron,et al. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis , 2018, Clinical pharmacology and therapeutics.
[10] J. Wallach,et al. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis , 2018, bioRxiv.
[11] J. Wallach,et al. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation , 2018, JAMA.
[12] J. Wallach,et al. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements , 2018, Clinical trials.
[13] J. Wallach,et al. The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation , 2018, Clinical trials.
[14] Lisa M. Schwartz,et al. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis , 2018, British Medical Journal.
[15] G. Baron,et al. Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study , 2018, International journal of cancer.
[16] G. Baron,et al. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study , 2017, BMJ Open.
[17] A. Jena,et al. The Trade-off Between Speed and Safety in Drug Approvals. , 2017, JAMA oncology.
[18] Lisa M. Schwartz,et al. The Fate of FDA Postapproval Studies. , 2017, The New England journal of medicine.
[19] R. Ware,et al. Sickle cell disease , 2017, The Lancet.
[20] J. Ioannidis,et al. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval , 2017, The Milbank quarterly.
[21] H. Krumholz,et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review , 2017, British Medical Journal.
[22] A. Breckenridge,et al. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines , 2017, Front. Pharmacol..
[23] Jonathan J. Darrow,et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study , 2015, BMJ : British Medical Journal.
[24] A. Kesselheim,et al. FDA Policy and Cardiovascular Medicine. , 2015, Circulation.
[25] C. Furberg,et al. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized , 2015, Drug Safety.
[26] Harlan M. Krumholz,et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.
[27] G. Alexander,et al. The Food and Drug Administration Amendments Act and postmarketing commitments. , 2013, JAMA.
[28] Christopher Moses,et al. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. , 2013, Population health management.
[29] J. DiMasi. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. , 2013, Clinical therapeutics.
[30] B. Psaty,et al. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. , 2012, JAMA.
[31] G. D. Dal Pan. Monitoring the Safety of Medicines Used Off‐Label , 2012, Clinical pharmacology and therapeutics.
[32] Thomas P. Gross,et al. The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.
[33] Asher Mullard,et al. 2010 FDA drug approvals , 2011, Nature Reviews Drug Discovery.
[34] Bethan Hughes,et al. 2009 FDA drug approvals , 2010, Nature Reviews Drug Discovery.
[35] Bethan Hughes,et al. 2008 FDA drug approvals , 2009, Nature Reviews Drug Discovery.
[36] I. Cockburn,et al. The Impact of Incremental Innovation in Biopharmaceuticals , 2006, PharmacoEconomics.
[37] P. Lane. Sickle cell disease. , 1996, Pediatric clinics of North America.
[38] Graham R Serjeant,et al. Sickle-cell disease , 1984, The Lancet.
[39] Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products , 1998 .